Allergan Plc (AGN) 336.73 $AGN
Fitch Affirms Allergan's 'BBB-' Ratings Following Generic Business Sale to Teva
Business Wire - 2 hrs 37 mins ago
Fitch Ratings has affirmed the ratings for Allergan plc (formerly known as Actavis plc; NYSE: AGN) and its subsidiaries. The Rating Outlook is Stable.
AGN: 336.73 (+9.75)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - 2 hrs 55 mins ago
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 181.60 (+2.71), AGN: 336.73 (+9.75), PPH: 73.79 (+0.60), EIS: 55.39 (+0.47), ISRA: 33.93 (+0.18), TEVA: 71.18 (-0.82)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - 2 hrs 59 mins ago
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 336.73 (+9.75), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Allergan (AGN) Stock Gaining on Canaccord Price Target Increase
at The Street - Tue Jul 28, 9:43AM CDT
Allergan (AGN) price target was raised to $396 from $352 at Canaccord which reiterating its 'buy' rating.
AGN: 336.73 (+9.75)
Critical Alerts For Alibaba, Allergan, Yelp, JC Penney and Cliffs Natural Resources Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, AGN, YELP, JCP and CLF.
AGN: 336.73 (+9.75), JCP: 8.26 (+0.02), CLF: 3.03 (+0.63), YELP: 33.55 (-0.18), BABA: 80.06 (-1.34)
Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:18AM CDT
Allergan plc (AGN) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGN: 336.73 (+9.75), ADMS: 26.67 (+0.52)
Allergan Kicks off REFRESH AMERICA Program to Supply First Responders With Free Eye Drops
PR Newswire - Tue Jul 28, 7:00AM CDT
First responders often work in conditions that can take a toll on their eyes. Exposure to heat, smoke, wind and dust may cause Dry Eye symptoms, such as irritated and painful eyes.[1] This is part of the day-to-day environmental challenges they must endure in order to do their job--saving lives. That is why today, Allergan is announcing the REFRESH AMERICA campaign to help our nation's best perform and alleviate their discomfort from dry eye. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line between 8/1/15 - 7/31/16 will lead to donations of REFRESH® eye drops to select first responder groups nationwide. Allergan guarantees a minimum product donation with an approximate retail value of $250,000, regardless of the number of eligible products sold during the campaign period.
AGN: 336.73 (+9.75)
Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
PR Newswire - Tue Jul 28, 6:00AM CDT
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (progesterone gel) under the mutual-recognition procedure (MRP).
AGN: 336.73 (+9.75), JNP: 9.78 (+0.20)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 336.73 (+9.75), KYTH: 74.50 (+0.15)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 336.73 (+9.75), SPY: 209.06 (+2.27), IYH: 161.55 (+2.33), QQQ: 111.02 (+0.84), DIA: 175.91 (+1.68), TEVA: 71.18 (-0.82), VIS: 103.25 (+1.73)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 336.73 (+9.75), QSR: 42.31 (+0.81), F: 14.89 (+0.34), QSR.TO: 54.73 (+0.52), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82), MHFI: 98.14 (-1.45)
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid
at The Street - Mon Jul 27, 4:47PM CDT
Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.
AGN: 336.73 (+9.75), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA
GlobeNewswire - Mon Jul 27, 4:45PM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's pending acquisition of KYTHERA.
AGN: 336.73 (+9.75), KYTH: 74.50 (+0.15)
Analysts expect more tie-ups in generic drug business
AP - Mon Jul 27, 3:43PM CDT
NEW YORK (AP) — Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan.
1 Comment
IPXL: 48.79 (-0.46), AGN: 336.73 (+9.75), AKRX: 47.12 (+0.96), SGNT: 25.49 (+0.01), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Stocks Fall For Fifth Straight Session On China Woes
at Investor's Business Daily - Mon Jul 27, 3:39PM CDT
Stocks fell for the fifth straight session Monday as a sell-off in China's main index sparked fears of a slowdown in the world's second-biggest economy. The Nasdaq fell 1%, sliding below its 50-day moving average. The Dow Jones industrial average...
AGN: 336.73 (+9.75), NFX: 31.45 (+0.57), CYBR: 59.85 (+0.02), SOHU: 43.94 (+1.20), TEVA: 71.18 (-0.82), MRO: 21.43 (+0.74), JD: 32.15 (unch), PAYC: 31.58 (-0.02), BABA: 80.06 (-1.34)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 336.73 (+9.75), BIIB: 317.44 (+8.01), GILD: 113.29 (+2.75), TEVA: 71.18 (-0.82), TWTR: 35.97 (+1.27)
Stocks Down in the Dumps as Chinese Market Slumps
at The Street - Mon Jul 27, 3:05PM CDT
Wall Street sees no fresh start to the week as stocks suffer their fifth day of losses on Monday.
KMI: 35.86 (+0.64), COP: 52.61 (+1.96), FCAU: 14.88 (+0.47), UBS: 22.52 (+0.54), SLB: 82.63 (+0.87), AGN: 336.73 (+9.75), QCOM: 63.37 (+1.39), DANG: 6.60 (+0.06), TEVA: 71.18 (-0.82), BP: 37.05 (+1.00), JD: 32.15 (unch), CVX: 92.10 (+2.96), PTR: 99.23 (+4.06), XLE: 70.58 (+2.07), BABA: 80.06 (-1.34)
Fitch Affirms Allergan's 'BBB-' Ratings Following Generic Business Sale to Teva
Business Wire - 2 hrs 37 mins ago
Fitch Ratings has affirmed the ratings for Allergan plc (formerly known as Actavis plc; NYSE: AGN) and its subsidiaries. The Rating Outlook is Stable.
AGN: 336.73 (+9.75)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - 2 hrs 55 mins ago
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 181.60 (+2.71), AGN: 336.73 (+9.75), PPH: 73.79 (+0.60), EIS: 55.39 (+0.47), ISRA: 33.93 (+0.18), TEVA: 71.18 (-0.82)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - 2 hrs 59 mins ago
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 336.73 (+9.75), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Allergan (AGN) Stock Gaining on Canaccord Price Target Increase
at The Street - Tue Jul 28, 9:43AM CDT
Allergan (AGN) price target was raised to $396 from $352 at Canaccord which reiterating its 'buy' rating.
AGN: 336.73 (+9.75)
Critical Alerts For Alibaba, Allergan, Yelp, JC Penney and Cliffs Natural Resources Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, AGN, YELP, JCP and CLF.
AGN: 336.73 (+9.75), JCP: 8.26 (+0.02), CLF: 3.03 (+0.63), YELP: 33.55 (-0.18), BABA: 80.06 (-1.34)
Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:18AM CDT
Allergan plc (AGN) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGN: 336.73 (+9.75), ADMS: 26.67 (+0.52)
Allergan Kicks off REFRESH AMERICA Program to Supply First Responders With Free Eye Drops
PR Newswire - Tue Jul 28, 7:00AM CDT
First responders often work in conditions that can take a toll on their eyes. Exposure to heat, smoke, wind and dust may cause Dry Eye symptoms, such as irritated and painful eyes.[1] This is part of the day-to-day environmental challenges they must endure in order to do their job--saving lives. That is why today, Allergan is announcing the REFRESH AMERICA campaign to help our nation's best perform and alleviate their discomfort from dry eye. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line between 8/1/15 - 7/31/16 will lead to donations of REFRESH® eye drops to select first responder groups nationwide. Allergan guarantees a minimum product donation with an approximate retail value of $250,000, regardless of the number of eligible products sold during the campaign period.
AGN: 336.73 (+9.75)
Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
PR Newswire - Tue Jul 28, 6:00AM CDT
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (progesterone gel) under the mutual-recognition procedure (MRP).
AGN: 336.73 (+9.75), JNP: 9.78 (+0.20)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 336.73 (+9.75), KYTH: 74.50 (+0.15)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 336.73 (+9.75), SPY: 209.06 (+2.27), IYH: 161.55 (+2.33), QQQ: 111.02 (+0.84), DIA: 175.91 (+1.68), TEVA: 71.18 (-0.82), VIS: 103.25 (+1.73)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 336.73 (+9.75), QSR: 42.31 (+0.81), F: 14.89 (+0.34), QSR.TO: 54.73 (+0.52), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82), MHFI: 98.14 (-1.45)
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid
at The Street - Mon Jul 27, 4:47PM CDT
Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.
AGN: 336.73 (+9.75), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA
GlobeNewswire - Mon Jul 27, 4:45PM CDT
Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's pending acquisition of KYTHERA.
AGN: 336.73 (+9.75), KYTH: 74.50 (+0.15)
Analysts expect more tie-ups in generic drug business
AP - Mon Jul 27, 3:43PM CDT
NEW YORK (AP) — Analysts say they expect more tie-ups are coming in the generic drug industry in the wake of Teva's mammoth deal for the generic drug business of Allergan.
1 Comment
IPXL: 48.79 (-0.46), AGN: 336.73 (+9.75), AKRX: 47.12 (+0.96), SGNT: 25.49 (+0.01), MYL: 55.64 (-0.73), TEVA: 71.18 (-0.82)
Stocks Fall For Fifth Straight Session On China Woes
at Investor's Business Daily - Mon Jul 27, 3:39PM CDT
Stocks fell for the fifth straight session Monday as a sell-off in China's main index sparked fears of a slowdown in the world's second-biggest economy. The Nasdaq fell 1%, sliding below its 50-day moving average. The Dow Jones industrial average...
AGN: 336.73 (+9.75), NFX: 31.45 (+0.57), CYBR: 59.85 (+0.02), SOHU: 43.94 (+1.20), TEVA: 71.18 (-0.82), MRO: 21.43 (+0.74), JD: 32.15 (unch), PAYC: 31.58 (-0.02), BABA: 80.06 (-1.34)
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
at The Street - Mon Jul 27, 3:30PM CDT
People are "max negative" on Twitter ahead of its earnings report Tuesday, which Jim Cramer doesn't see as unjustified -- at least, in the short term.
AGN: 336.73 (+9.75), BIIB: 317.44 (+8.01), GILD: 113.29 (+2.75), TEVA: 71.18 (-0.82), TWTR: 35.97 (+1.27)
Stocks Down in the Dumps as Chinese Market Slumps
at The Street - Mon Jul 27, 3:05PM CDT
Wall Street sees no fresh start to the week as stocks suffer their fifth day of losses on Monday.
KMI: 35.86 (+0.64), COP: 52.61 (+1.96), FCAU: 14.88 (+0.47), UBS: 22.52 (+0.54), SLB: 82.63 (+0.87), AGN: 336.73 (+9.75), QCOM: 63.37 (+1.39), DANG: 6.60 (+0.06), TEVA: 71.18 (-0.82), BP: 37.05 (+1.00), JD: 32.15 (unch), CVX: 92.10 (+2.96), PTR: 99.23 (+4.06), XLE: 70.58 (+2.07), BABA: 80.06 (-1.34)
